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1. BACKGROUND {#mgg3955-sec-0005}
=============

Coronary heart disease (CHD) is one of the most common cause of morbidity and mortality in cardiovascular diseases (CVD) worldwide, especially in the developed countries (Gaunt & Davey, [2015](#mgg3955-bib-0009){ref-type="ref"}). CHD is characterized by the deposition of excessive cholesterol in the arterial intima (Lusk et al., [2014](#mgg3955-bib-0022){ref-type="ref"}). The interaction of genetic and environmental factors can explain the majority of CHD cases (Peyser, [1997](#mgg3955-bib-0024){ref-type="ref"}). Genetic factors play a vital role in the occurrence and development of CHD (Cunnington, Koref, Mayosi, Burn, & Keavney, [2010](#mgg3955-bib-0007){ref-type="ref"}; Roberts, [2014](#mgg3955-bib-0027){ref-type="ref"}). Single nucleotide polymorphisms (SNPs) are the most frequent genetic variation. Therefore, further exploration of the gene SNPs is much more significant and helpful for specific diagnosis on CHD.

*Cyclin‐dependent kinase inhibitor 2B antisense RNA 1* (*CDKN2B‐AS1*), also called *ANRIL*, is located within the *CDKN2A‐CDKN2B* cluster. Its product is a functional RNA molecule that interacts with polycomb repressive complex‐1 (PRC1) and ‐2 (PRC2), leading to epigenetic silencing of other genes in this cluster (Jing et al., [2018](#mgg3955-bib-0016){ref-type="ref"}). *CDKN2B‐AS1* is expressed in vascular endothelial cells and coronary smooth muscle cells (Broadbent et al., [2008](#mgg3955-bib-0002){ref-type="ref"}). The regulation of *CDKN2B‐AS1* expression level affects vascular cell proliferation and senescence. Genome‐wide association studies (GWAS) have reported that *CDKN2B‐AS1* contains multiple genetic markers for CHD (Kunnas, Piesanen, & Nikkari, [2018](#mgg3955-bib-0020){ref-type="ref"}). Genetic variants of *CDKN2B‐AS1* are related to CVD by mediating the response to inflammatory signalling (Harismendy et al., [2011](#mgg3955-bib-0012){ref-type="ref"}). However, the definite polymorphisms of *CDKN2B‐AS1* affect CHD risk remain unclear, especially in the subgroups of age, gender, CHD patients with hypertension, and diabetes. Previous studies have shown that *CDKN2B‐AS1* polymorphisms are associated with susceptibility to many diseases, including brain diseases (Sun et al., [2017](#mgg3955-bib-0029){ref-type="ref"}), gout (Hsu et al., [2012](#mgg3955-bib-0014){ref-type="ref"}), myocardial infarction (MI; Ivanova et al., [2017](#mgg3955-bib-0015){ref-type="ref"}), and cancers (Gong et al., [2017](#mgg3955-bib-0011){ref-type="ref"}). Although there have been several studies about the relationship between rs1333049 and CHD risk, the conclusions were not entirely consistent (Foroughmand, Nikkhah, Galehdari, & Jadbabaee, [2015](#mgg3955-bib-0008){ref-type="ref"}; Lian et al., [2014](#mgg3955-bib-0021){ref-type="ref"}; Pignataro et al., [2017](#mgg3955-bib-0025){ref-type="ref"}; Pinós et al., [2014](#mgg3955-bib-0026){ref-type="ref"}). Moreover, there were no studies regarding the association of rs10115049, rs75227345, rs2383205, rs10738606, and CHD susceptibility.

Hence, we conducted a case--control study to investigate the association of *CDKN2B‐AS1* polymorphisms (rs10115049, rs75227345, rs2383205, rs10738606, and rs1333049) and CHD risk in the Chinese Han population.

2. METHODS {#mgg3955-sec-0006}
==========

2.1. Study subjects {#mgg3955-sec-0007}
-------------------

This study included 501 CHD patients (320 males and 181 females) and 496 healthy controls (318 males and 178 females) enrolled from Central South University Xiangya School of Medicine Affiliated Haikou Hospital, China. Patients were diagnosed with CHD according to standardized coronary angiography. The healthy controls were healthy individuals determined by medical history and clinical examinations. The healthy controls who had congenital heart disease, family history of CVD or known disease, were excluded in this study. The demographic and clinical characteristics of the participants are recorded in Table [1](#mgg3955-tbl-0001){ref-type="table"}. Our study protocol was approved by the Medical Ethics Committees of Central South University Xiangya School of Medicine Affiliated Haikou Hospital. And written informed consent was obtained from all study objects.

###### 

Demographic and clinical characteristics of the study objects

  -------------------------------------------------------------------
  Characteristics   CHD patients\    Healthy controls\   *p*
                    (*N* = 501)      (*N* = 496)         
  ----------------- ---------------- ------------------- ------------
  Age, years        61.32 ± 11.70    60.69 ± 6.43        .289

  \>61              250 (49.9%)      233 (47.0%)         

  ≤61               251 (50.1%)      263 (53.0%)         

  Sex                                                    

  Male              320 (63.9%)      318 (64.1%)         .895

  Female            181 (36.1%)      178 (35.9%)         

  HDL (mmol/L)      1.13 ± 0.25      1.09 ± 0.23         **\<.001**

  LDL (mmol/L)      1.92 ± 0.82      2.55 ± 0.71         **\<.001**

  PLT (10^9^/L)     169.37 ± 75.18   211.10 ± 55.50      **\<.001**

  PDW (%)           14.30 ± 2.87     13.74 ± 2.87        **.010**

  MPV (FL)          13.01 ± 7.14     10.91 ± 1.23        **\<.001**

  PCT (%)           1.08 ± 3.151     0.30 ± 0.89         **\<.001**

  WBC               11.68 ± 15.45    5.93 ± 1.50         **\<.001**

  RBC               14.72 ± 35.86    4.84 ± 0.45         **\<.001**

  HGB               132.67 ± 31.56   148.48 ± 14.77      **\<.001**

  Urea              5.81 ± 6.51      7.01 ± 21.29        .241

  UA (μmol/L)       292.30 ± 88.75   330.55 ± 82.58      **\<.001**

  TG (mmol/L)       1.78 ± 1.48      1.77 ± 1.13         .947

  TC (mmol/L)       4.09 ± 1.16      4.82 ± 5.47         **.006**

  Hypertension      296 (60%)                            

  Diabetes          101 (20%)                            

  Gastritis         59 (12%)                             
  -------------------------------------------------------------------

Numbers in bold mean statistical significance.

Abbreviations: CHD, coronary heart disease; HDL, high‐density lipoprotein; HGB, hemoglobin; LDL, low‐density lipoprotein; MPV, mean platelet volume; PCT, plateletcrit; PDW, platelet distribution width; PLT, platelet; RBC, red blood cells; TC, total cholesterol; TG, triglyceride; UA, uric acid; WBC, white blood cells.
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2.2. SNP selection and genotyping {#mgg3955-sec-0008}
---------------------------------

Genomic DNA was extracted from peripheral blood stored with EDTA using blood DNA kit (GoldMag Co. Ltd.). The concentration of the DNA samples was measured with Nanodrop 2000 (Thermo Scientific). In this study, five SNPs in *CDKN2B‐AS1* were selected from UCSC database and each candidate SNP had larger than 5% minor allele frequency in Chinese Han population. The primers used in this study were designed using MassARRAY Assay Design 3.0 software (Table [S1](#mgg3955-sup-0001){ref-type="supplementary-material"}), and the genotyping was performed on the MassARRAY iPLEX platform (Agena Bioscience) (Sun et al., [2017](#mgg3955-bib-0029){ref-type="ref"}). We checked the quality of the genotype determination by the same method. We predicted functions of selected polymorphisms by HaployReg v4.1. Agena Bioscience TYPER version 4.0 software was used to perform data management and analyses.

2.3. Statistical analysis {#mgg3955-sec-0009}
-------------------------

Differences in categorical and continuous variables between cases and controls were assessed using the chi‐squared test and *t* test, respectively. Hardy--Weinberg equilibrium (HWE) was conducted for each SNP in controls using Fisher\'s exact test. Genotype and allele distributions were compared using the chi‐squared test. The relationships between *CDKN2B‐AS1* polymorphisms and CHD risk were evaluated in multiple genetic models using PLINK software. Odds ratios (OR) and 95% confidence intervals (CI) were calculated using logistic regression analysis after adjusting with gender and age. In addition, haplotype analysis and linkage disequilibrium (LD) were conducted by PLINK software and Haploview software (version 4.2; Kaushal et al., [2007](#mgg3955-bib-0018){ref-type="ref"}). All statistical analyses were performed using the SPSS 17.0 (IBM®). The *p*‐values were two‐sided in our study, and *p* \< .05 was considered statistical significant.

3. RESULTS {#mgg3955-sec-0010}
==========

3.1. Characteristics of the study objects {#mgg3955-sec-0011}
-----------------------------------------

A total of 501 CHD cases (mean age: 61.32 ± 11.70) and 496 healthy controls (mean age: 60.69 ± 6.43) were included in this study. Demographic and clinical characteristics of the study objects that include age, sex, high‐density lipoprotein (HDL), low‐density lipoprotein (HDL), platelet (PLT), platelet distribution width (PDW), mean platelet volume (MPV), plateletcrit (PCT), white blood cells (WBC), red blood cells (RBC), hemoglobin (HGB), urea, uric acid (UA), triglyceride (TG), total cholesterol (TC) are shown in Table [1](#mgg3955-tbl-0001){ref-type="table"}. There were no significant differences in the age and sex distribution between two groups (*p* \> .05). Among the CHD patients, 296 (60%) individuals with hypertension, 101 (20%) individuals with diabetes, and 59 (12%) individuals had gastritis.

3.2. Associations between *CDKN2B‐AS1* polymorphisms and CHD risk {#mgg3955-sec-0012}
-----------------------------------------------------------------

As shown in Table [2](#mgg3955-tbl-0002){ref-type="table"}, the genotype distributions of all the five SNPs in controls met HWE (*p* \> .05). Genotype and allele frequencies of *CDKN2B‐AS1* polymorphisms are listed in Table [2](#mgg3955-tbl-0002){ref-type="table"}. In Table [S2](#mgg3955-sup-0001){ref-type="supplementary-material"}, all *CDKN2B‐AS1* polymorphisms are located in intronic region, and these SNPs are related to the regulation of DNAse, Motifs changed, Selected eQTL hits, Enhancer histone marks and NHGRI/EBI GWAS hits. In Table [3](#mgg3955-tbl-0003){ref-type="table"}, logistic regression analyses revealed that rs10738606 conferred a decreased risk of CHD in codominant (OR = 0.54, 95% CI = 0.36--0.81, *p* = .003), dominant (OR = 0.74, 95% CI = 0.57--0.95, *p* = .019), recessive (OR = 0.60, 95% CI = 0.41--0.89, *p* = .010) and additive (OR = 0.75, 95% CI = 0.63--0.91, *p* = .003) models. A allele carriers of rs10738606 significantly decreased CHD risk (OR = 0.76, 95% CI = 0.63--0.91, *p* = .003). No significant associations were observed in the other *CDKN2B‐AS1* polymorphisms and CHD risk (*p* \> .05).

###### 

Comparison of genotype and allele frequencies between cases and controls

  SNP          Location: Position   Groups        Genotype (counts)   *p*        Allele (counts)   *p*           MAF        HWE *p*              
  ------------ -------------------- ------------- ------------------- ---------- ----------------- ------------- ---------- --------- ------- -- --
  rs10115049   Chr9: 22032120                     AA                  GA         GG                              A          G                    
  Cases        73 (14.6%)           208 (41.5%)   220 (43.9%)                    354 (35.3%)       648 (64.7%)              0.353                
  Controls     63 (12.7%)           227 (45.8%)   206 (41.5%)         .370       353 (35.6%)       639 (64.4%)   .905       0.356     1.000      
  rs75227345   Chr9: 22042298                     TT                  TC         CC                              T          C                    
  Cases        26 (5.2%)            139 (27.7%)   336 (67.1%)                    191 (19.1%)       811 (80.9%)              0.191                
  Controls     17 (3.4%)            127 (25.6%)   352 (71.0%)         .257       161 (16.2%)       831 (83.8%)   .097       0.162     0.188      
  rs2383205    Chr9: 22060936                     AA                  GA         GG                              A          G                    
  Cases        10 (2.0%)            115 (23.0%)   376 (75.0%)                    135 (13.5%)       867 (86.5%)              0.134                
  Controls     13 (2.6%)            133 (26.8%)   350 (50.4%)         .265       159 (16.0%)       833 (84.0%)   .108       0.160     0.869      
  rs10738606   Chr9: 22088091                     AA                  AT         TT                              A          T                    
  Cases        48 (9.6%)            224 (45.0%)   226 (45.4%)                    320 (32.1%)       606 (67.9%)              0.321                
  Controls     74 (15.0%)           230 (46.7%)   188 (38.3%)         **.011**   378 (38.4%)       676 (61.6%)   **.003**   0.384     0.776      
  rs1333049    Chr9: 22125504                     CC                  CG         GG                              C          G                    
  Cases        110 (22.0%)          263 (52.5%)   128 (25.5%)                    483 (48.2%)       519 (51.8%)              0.482                
  Controls     94 (19.0%)           254 (51.2%)   148 (29.8%)         .241       442 (44.6%)       550 (55.4%)   .103       0.446     0.467      

Numbers in bold mean statistical significance.

Abbreviations: HWE, Hardy--Weinberg equilibrium; MAF, minor allele frequency; SNP, single nucleotide polymorphism.
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###### 

The association between *CDKN28‐AS1* polymorphisms and CHD risk

  SNP          Model               Genotype/Allele     OR (95％CI)         *p*
  ------------ ------------------- ------------------- ------------------- ----------
  rs10115049   Codominant          AA/GG               1.08 (0.73--1.59)   .690
  GA/GG        0.86 (0.66--1.12)   .257                                    
  Dominant     AA‐AG/GG            0.91 (0.70--1.16)   .438                
  Recessive    AA/AG‐GG            1.17 (0.81--1.68)   .396                
  Additive                         0.99 (0.83--1.18)   .894                
  Allele       A/G                 0.99 (0.82--1.19)   .905                
  rs75227345   Codominant          TT/CC               1.59 (0.85--2.99)   .147
  TC/CC        1.15 (0.87--1.53)   .332                                    
  Dominant     TT‐CT/CC            1.20 (0.92--1.58)   .178                
  Recessive    TT/CT‐CC            1.53 (0.82--2.86)   .181                
  Additive                         1.20 (0.96--1.50)   .110                
  Allele       T/C                 1.22 (0.96--1.53)   .097                
  rs2383205    Codominant          AA/GG               0.72 (0.31--1.66)   .435
  GA/GG        0.80 (0.60--1.07)   .130                                    
  Dominant     AA‐AG/GG            0.79 (0.60--1.05)   .104                
  Recessive    AA/AG‐GG            0.76 (0.33--1.75)   .515                
  Additive                         0.81 (0.64--1.04)   .103                
  Allele       A/G                 0.82 (0.64--1.05)   .108                
  rs10738606   Codominant          AA/TT               0.54 (0.36--0.81)   **.003**
  TA/TT        0.80 (0.61--1.05)   .108                                    
  Dominant     AA‐AT/TT            0.74 (0.57--0.95)   **.019**            
  Recessive    AA/AT‐TT            0.60 (0.41--0.89)   **.010**            
  Additive                         0.75 (0.63--0.91)   **.003**            
  Allele       A/T                 0.76 (0.63--0.91)   **.003**            
  rs1333049    Codominant          CC/GG               1.36 (0.95--1.96)   .095
  GC/GG        1.20 (0.90--1.61)   .218                                    
  Dominant     CC‐CG/GG            1.25 (0.94--1.65)   .122                
  Recessive    CC/GC‐GG            1.21 (0.89--1.65)   .231                
  Additive                         1.17 (0.98--1.40)   .089                
  Allele       C/G                 1.16 (0.97--1.38)   .103                

Numbers in bold mean statistical significance.

Abbreviations: 95% CI, 95% confidence interval; CHD, coronary heart disease; OR, odds ratio; SNP, single nucleotide polymorphism.
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3.3. Associations between *CDKN2B‐AS1* polymorphisms and CHD risk in subgroups {#mgg3955-sec-0013}
------------------------------------------------------------------------------

The relationships between *CDKN2B‐AS1* polymorphisms and CHD risk were further assessed in four subgroups (age, gender, hypertension, and diabetes). The significant associations were presented in Table [4](#mgg3955-tbl-0004){ref-type="table"}. Rs75227345, rs2383205, rs10738606, and rs1333049 were associated with CHD risk in males. Rs75227345 and rs1333049 increased the risk of CHD (rs75227345: homozygote, OR = 2.62, 95% CI = 1.07--6.44, *p* = .036; recessive: OR = 2.49, 95% CI = 1.02--6.10, *p* = .045; additive: OR = 1.35, 95% CI = 1.01--1.81, *p* = .040; allele: OR = 1.38, 95% CI = 1.03--1.86, *p* = .033; rs1333049: homozygote, OR = 1.67, 95% CI = 1.06--2.64, *p* = .027; recessive: OR = 1.59, 95% CI = 1.08--2.37, *p* = .018; additive: OR = 1.28, 95% CI = 1.02--1.60, *p* = .034; allele: OR = 1.26, 95% CI = 1.01--1.58, *p* = .037), whereas rs2383205 and rs10738606 decreased CHD risk (rs2383205: dominant, OR = 0.67, 95% CI = 0.47--0.97, *p* = .035; additive, OR = 0.67, 95% CI = 0.48--0.92, *p* = .014; allele, OR = 0.67, 95% CI = 0.49--0.93, *p* = .014; rs10738606, homozygote, OR = 0.44, 95% CI = 0.27--0.73, *p* = .001; dominant, OR = 0.64, 95% CI = 0.47--0.88, *p* = .006; recessive, OR = 0.52, 95% CI = 0.33--0.84, *p* = .007; additive, OR = 0.68, 95% CI = 0.54--0.85, *p* = .001; allele, OR = 0.67, 95% CI = 0.53--0.85, *p* \< .001). For the individuals equal or younger than 61 years old, rs2383205 had a lower risk of CHD in heterozygote (OR = 0.61, 95% CI = 0.39--0.95, *p* = .030) and dominant (OR = 0.63, 95% CI = 0.41--0.97, *p* = .035) models. Among the elderly group (age \> 61), rs10738606‐A allele was a protective factor of CHD (OR = 0.74, 95% CI = 0.57--0.96, *p* = .023). In addition, we found that rs1333049 decreased the risk of diabetes for CHD patients (heterozygote, OR = 0.53, 95% CI = 0.32--0.88, *p* = .014; dominant: OR = 0.58, 95% CI = 0.36--0.93, *p* = .024).

###### 

The association between *CDKN28‐AS1* polymorphisms and CHD risk in the subgroups

  SNP          Subgroup            Homozygote          Heterozygote        Dominant            Recessive           Additive            Allele                                                                                                                  
  ------------ ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- ----------
  rs75227345   Male                2.62 (1.07--6.44)   **.036**            1.21 (0.84--1.73)   .309                1.32 (0.94--1.86)   .109                2.49 (1.02--6.10)   **.045**            1.35 (1.01--1.81)   **.040**            1.38 (1.03--1.86)   **.033**
  rs2383205    Age ≤ 61            0.89 (0.23--3.45)   .864                0.61 (0.39--0.95)   **.030**            0.63 (0.41--0.97)   **.035**            1.01 (0.26--3.91)   .987                1.01 (0.26--3.91)   .987                0.72 (0.51--1.03)   .071
  Male         0.30 (0.08--1.12)   0.072               0.71 (0.49--1.02)   .065                0.67 (0.47--0.96)   **.028**            0.32 (0.09--1.21)   .094                0.67 (0.48--0.92)   **.014**            0.67 (0.49--0.93)   **.014**            
  rs10738606   Age \> 61           0.60 (0.33--1.08)   .089                0.86 (0.58--1.28)   .453                0.79 (0.54--1.15)   .217                0.64 (0.37--1.13)   .124                0.80 (0.61--1.04)   .100                0.74 (0.57--0.96)   **.023**
  Male         0.44 (0.27--0.73)   **.001**            0.72 (0.51--1.00)   .051                0.64 (0.47--0.88)   **.006**            0.52 (0.33--0.84)   **.007**            0.68 (0.54--0.85)   **.001**            0.67 (0.53--0.85)   **\<.001**          
  rs1333049    Male                1.67 (1.06--2.64)   **.027**            1.08 (0.74--1.56)   .698                1.22 (0.86--1.73)   .264                1.59 (1.08--2.34)   **.018**            1.28 (1.02--1.60)   **.034**            1.26 (1.01--1.58)   **.037**
  Diabetes     0.72 (0.39--1.32)   .284                0.53 (0.32--0.88)   **.014**            0.58 (0.36--0.93)   **.024**            1.07 (0.63--1.82)   .791                0.81 (0.59--1.12)   .199                0.81 (0.60--1.11)   .187                

Numbers in bold mean statistical significance.

Abbreviations: 95% CI, 95% confidence interval; CHD, coronary heart disease; OR, odds ratio; SNP, single nucleotide polymorphism.
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3.4. Genotypes and clinical characteristics {#mgg3955-sec-0014}
-------------------------------------------

We evaluated the association between genotypes of *CDKN2B‐AS1* polymorphisms and clinical characteristics of patients, including HDL, LDL, PLT, PDW, MPV, PCT, WBC, RBC, HGB, urea, UA, TG, and TC (Table [S3](#mgg3955-sup-0001){ref-type="supplementary-material"} and Table [5](#mgg3955-tbl-0005){ref-type="table"}). We observed that patients carried different genotypes of *CDKN2B*‐rs75227345 had significant differences in MPV, PCT, WBC, RBC, and HGB (*p* \< .05).

###### 

Clinical characteristics of rs75227345 on CHD patients

  Characteristics   *CDKN2B*‐rs75227345                                     
  ----------------- --------------------- ---------------- ---------------- ----------
  HDL (mmol/L)      1.10 ± 0.29           1.13 ± 0.24      1.14 ± 0.26      .786
  LDL (mmol/L)      1.84 ± 0.60           1.96 ± 0.82      1.91 ± 0.84      .753
  PLT (10^9^/L)     170.77 ± 37.87        157.71 ± 80.58   174.15 ± 74.70   .097
  PDW (%)           14.08 ± 2.61          14.41 ± 3.13     14.28 ± 2.80     .846
  MPV (FL)          11.08 ± 0.93          14.18 ± 8.67     12.67 ± 6.64     **.044**
  PCT (%)           0.19 ± 0.04           1.60 ± 3.72      0.93 ± 2.98      **.038**
  WBC               7.03 ± 2.65           14.83 ± 20.20    10.72 ± 13.42    **.009**
  RBC               4.82 ± 0.75           22.02 ± 46.70    12.44 ± 31.35    **.011**
  HGB               138.00 ± 20.16        125.37 ± 36.47   135.23 ± 29.61   **.006**
  Urea              5.43 ± 2.53           5.75 ± 2.11      5.86 ± 7.80      .942
  UA (μmol/L)       309.72 ± 81.47        297.77 ± 82.16   288.74 ± 91.79   .372
  TG (mmol/L)       1.69 ± 1.10           1.88 ± 1.67      1.75 ± 1.43      .644
  TC (mmol/L)       3.93 ± 1.01           4.27 ± 1.31      4.03 ± 1.09      .110

Numbers in bold mean statistical significance.

Abbreviations: CHD, coronary heart disease; HDL, high‐density lipoprotein; HGB, hemoglobin; LDL, low‐density lipoprotein; MPV, mean platelet volume; PCT, plateletcrit; PDW, platelet distribution width; PLT, platelet; RBC, red blood cells; TC, total cholesterol; TG, triglyceride; UA, uric acid; WBC, white blood cells.
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3.5. Haplotype analysis of *CDKN2B‐AS1* polymorphisms and CHD risk {#mgg3955-sec-0015}
------------------------------------------------------------------

We also performed haplotype analysis of *CDKN2B‐AS1* polymorphisms and CHD risk. We found one block including rs10115049 and rs75227345 (Figure [1](#mgg3955-fig-0001){ref-type="fig"}). As shown in Table [S4](#mgg3955-sup-0001){ref-type="supplementary-material"}, there was no significantly association between haplotypes of *CDKN2B‐AS1* polymorphisms and CHD risk (*p* \> .05).

![Linkage disequilibrium plots containing five polymorphisms from *CDKN2B‐AS1*. Block 1 includes rs10115049 and rs75227345. The numbers inside the diamonds indicate the D′ for pairwise analyses](MGG3-7-e955-g001){#mgg3955-fig-0001}

4. DISCUSSION {#mgg3955-sec-0016}
=============

In this study, we genotyped five SNPs of *CDKN2B‐AS1* and evaluated the association between these SNPs and CHD risk in the Chinese Han population. We found that *CDKN2B‐AS1* polymorphisms had strong relationships with CHD risk, especially rs10738606 could protect the Chinese Han population from CHD. Age, sex, and complications of CHD significantly influenced the association of *CDKN2B‐AS1* polymorphisms and CHD risk. Our results gave a clue in the prevention, diagnosis, and individual treatment of CHD.

*CDKN2B‐AS1* encodes a 3.8 kb lnc RNA which consists of 19 exons, and is located at chromosome 9p21 (Holdt et al., [2011](#mgg3955-bib-0013){ref-type="ref"}; Kong, Sharma, Nwosu, & Alonso, [2016](#mgg3955-bib-0019){ref-type="ref"}). The 9p21.3 locus was first identified by GWAS to be strongly associated with CHD and MI (Glinsky, [2008](#mgg3955-bib-0010){ref-type="ref"}; Ruth et al., [2007](#mgg3955-bib-0028){ref-type="ref"}). It then reported that this locus was associated with PLT reactivity and polymorphisms at 9p21 influence inflammatory signaling and vascular cell proliferation (Harismendy et al., [2011](#mgg3955-bib-0012){ref-type="ref"}; Musunuru et al., [2010](#mgg3955-bib-0023){ref-type="ref"}; Visel et al., [2010](#mgg3955-bib-0030){ref-type="ref"}). We observed significant difference in PLT between CHD patients and healthy controls, and genotypes of rs75227345 also associated with PLT, it may explain the association of polymorphism with CHD. According to several published studies, rs2383206, rs10757274, and rs10757278 may serve as genetic biomarkers of CHD in Caucasians, East Asians, and West Asian (Wang, Dong, & Yang, [2016](#mgg3955-bib-0031){ref-type="ref"}). The expression of *CDKN2B‐AS1* genetic variants could influence CHD susceptibility in the Iranian patients (Bochenek et al., [2013](#mgg3955-bib-0001){ref-type="ref"}). Among the selected SNPs, rs1333049 is the frequently studied polymorphism. Rs1333049 was found to be associated with CHD in the Turkish (Cakmak et al., [2015](#mgg3955-bib-0003){ref-type="ref"}), Indians (Kashyap et al., [2018](#mgg3955-bib-0017){ref-type="ref"}), Japanese (Pinós et al., [2014](#mgg3955-bib-0026){ref-type="ref"}) population, but no studies focused on the Chinese population. As shown in our study, rs1333049 was remarkably associated with CHD susceptibility in subgroups. In addition, we found rs10738606 was a protective factor for CHD.

Age and gender disparities widely existed in the prevalence of CHD (Chen et al., [2016](#mgg3955-bib-0004){ref-type="ref"}; Cline & Beckie, [2013](#mgg3955-bib-0005){ref-type="ref"}). The incidence of CHD is 0.6% for the people younger than 40 years old, it will increase twofold or more with aging (Yan et al., [2013](#mgg3955-bib-0033){ref-type="ref"}). In our study, rs2383205 was associated with a decreased CHD risk among younger people (age ≤ 61), whereas rs10738606 decreased CHD risk among elderly people (age \> 61). It revealed an age‐based mechanism on the genetic variations. Previous studies have indicated that gender differences could influence gene expression and then affect disease progression (Coban et al., [2014](#mgg3955-bib-0006){ref-type="ref"}; Xu et al., [2008](#mgg3955-bib-0032){ref-type="ref"}). We found rs75227345, rs2383205, rs10738606, and rs1333049 had relationships with CHD risk in males, no associations were found in females. It confirmed previous results. Additionally, hypertension and diabetes are considered as traditional risk factors of CHD. In this study, we studied the relationship of *CDKN2B‐AS1* polymorphisms and complications (hypertension and diabetes) among CHD cases. Rs1333049 could protect CHD patients from diabetes under heterozygote and dominant models. Nevertheless, larger sample size and well‐designed studies are required to validate our results.

Some limitations could not be ignored in this study. First, all samples were collected from hospital, which inevitably exist the choosing bias. Second, we did not evaluate some factor that could have effects on CHD risk, because of a lack of data from both CHD patients and healthy controls. Third, this study did not analysis the mechanisms of *CDKN2B‐AS1* polymorphisms influence CHD risk. Further experiments on cell or animal level are required to explain the detailed molecular mechanism.

5. CONCLUSION {#mgg3955-sec-0017}
=============

Our results indicate that *CDKN2B‐AS1* polymorphisms are associated with CHD risk in the Chinese Han population. These SNPs may serve as biomarkers for CHD in the Chinese Han population.
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